Nextcell Pharma Ab
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2014-03-19
- Employees
- 11
- Market Cap
- -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
Phase 1
Active, not recruiting
- Conditions
- COVID-19 Acute Respiratory Distress SyndromeRespiratory Syncytial Virus (RSV)Influenza AMetapneumovirus Pneumonia
- Interventions
- Biological: ProTrans®
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 9
- Registration Number
- NCT04896853
- Locations
- 🇸🇪
Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden
Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 15
- Registration Number
- NCT03973827
- Locations
- 🇸🇪
Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
Phase 1
Completed
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- NextCell Pharma Ab
- Target Recruit Count
- 24
- Registration Number
- NCT03406585
- Locations
- 🇸🇪
Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath